• Most Popular
  • Most Shared

India Ranbaxy settles with GlaxoSmithKline on Imitrex

Mon Jan 21, 2008 12:11am EST

Stocks

   

MUMBAI, Jan 21 (Reuters) - Indian drugmaker Ranbaxy Laboratories Ltd (RANB.BO) said on Monday it had settled with GlaxoSmithKline (GSK.L) on a possible patent litigation for a generic version of the firm's Imitrex tablets, propping its share up in a falling market.

Stocks

Under the terms of the settlement, Ranbaxy may sell a generic version, sumatriptan succinate tablets, in multiple strengths in the United States from December 2008, it said in a statement.

Other terms of the settlement agreement were not disclosed.

Annual sales of Imitrex were $985 million, Ranbaxy estimates.

At 0510 GMT, Ranbaxy's shares were up 0.9 percent at 390 rupees, while the benchmark index .BSESN was down 2.8 percent. (Reporting by Rina Chandran; Editing by Charlotte Cooper)



More from Reuters

Photo

Euro zone holds intensive talks on Greek rescue

BERLIN/ATHENS (Reuters) - Euro zone countries held intensive talks on Wednesday on a possible rescue for Greece, whose debt crisis has shaken the entire currency union, as civil servants staged the first big strike against Athens' austerity plans. | Video

 A protester marches next to a banner during an anti-government rally in Athens February 10, 2010. REUTERS/John Kolesidis
Analysis:

Will IMF step in on Greece?

Europe is loathe to turn to the International Monetary Fund to help bail out Greece but it may have little choice.  Full Article 

A worker drives a Toyota Motor Corp's newly assembled Prius hybrid vehicle onto a trailer near the company's plant in Toyota, central Japan February 9, 2010.REUTERS/Yuriko Nakao
Reuters Breakingviews:

Toyota's troubles in overdrive

The cost of Toyota's recall nightmare is nothing compared to the price of fixing its battered reputation.  Commentary